Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology firm specializing in gene therapies for blindness, has announced it will hold a conference call and live webcast on March 4, 2026, at 8:30 a.m. ET. This event aims to discuss the Company’s financial performance for the fourth quarter and full year of 2025, in addition to providing a comprehensive update on its business activities. A pre-market earnings announcement will accompany the call, allowing investors and stakeholders to gain insight into the Company’s financial health and strategic direction.

Participants can join the conference via dial-in numbers with (800) 715-9871 for U.S. callers and (646) 307-1963 for international attendees, using the Conference ID 3029428. Additionally, the call will be available as a live webcast on the investor section of the Ocugen website. A replay of the conference and an archived version of the webcast will also be accessible for later review.

Ocugen is recognized for its innovative approach in addressing significant unmet medical needs in the field of inherited retinal diseases. The Company’s modifier gene therapy platform is particularly distinct as it targets complex diseases that arise from multiple gene imbalances, differentiating it from traditional gene therapies. Current therapeutic programs focus on serious conditions such as retinitis pigmentosa, Stargardt disease, and geographic atrophy associated with late-stage dry age-related macular degeneration.

As Ocugen prepares for this important communication, it also includes a cautionary note on forward-looking statements, emphasizing the potential risks and uncertainties that may impact outcomes discussed during the conference. For more information, stakeholders are encouraged to explore Ocugen's website and follow the Company on social media platforms such as X and LinkedIn.

As Ocugen, Inc. approaches its upcoming conference call on March 4, 2026, investors should closely scrutinize the company’s financial results and strategic updates. Ocugen has positioned itself as a leader in the field of gene therapies, particularly focused on treating various inherited retinal diseases that affect millions globally. The upcoming fourth quarter and full year 2025 results will be crucial for gauging the company's financial health and progress within this innovative market.

Investors should look for insights regarding revenue figures, R&D expenditures, and updates on clinical trial progress, particularly concerning therapies for conditions such as retinitis pigmentosa, Stargardt disease, and geographic atrophy of AMD. The company's modified gene therapy platform, which aims to tackle complex diseases by addressing multiple gene networks, presents a unique opportunity that could be transformative in the biotechnology sector.

Market sentiment towards Ocugen will depend heavily on the outcomes of this call. Positive clinical trial updates and a strong financial performance might bolster stock prices and enhance investor confidence. Conversely, any delays, increased expenses, or unfavorable results could lead to significant volatility.

Additionally, it’s important to consider the broader market dynamics, including regulatory factors and competition in the gene therapy space. Ocugen's potential partnerships or collaborations may also be a focus area during the call, as they could provide additional resources and validation for its pipeline.

Therefore, investors should prepare for the conference by researching these factors, considering potential risks, and staying updated on market trends. This strategic preparation will aid in making informed decisions based on the insights provided during the call.